AU2006256771A1 - Indole derivatives having antitumor activity - Google Patents

Indole derivatives having antitumor activity Download PDF

Info

Publication number
AU2006256771A1
AU2006256771A1 AU2006256771A AU2006256771A AU2006256771A1 AU 2006256771 A1 AU2006256771 A1 AU 2006256771A1 AU 2006256771 A AU2006256771 A AU 2006256771A AU 2006256771 A AU2006256771 A AU 2006256771A AU 2006256771 A1 AU2006256771 A1 AU 2006256771A1
Authority
AU
Australia
Prior art keywords
indol
bis
compound
tumour
heptanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006256771A
Other languages
English (en)
Inventor
Gianfranco Battistuzzi
Maria Di Marzo
Giuseppe Giannini
Mauro Marzi
Claudio Pisano
Loredana Vesci
Franco Zunino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU2006256771A1 publication Critical patent/AU2006256771A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
AU2006256771A 2005-06-10 2006-05-31 Indole derivatives having antitumor activity Abandoned AU2006256771A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05012562.4 2005-06-10
EP05012562 2005-06-10
PCT/EP2006/062798 WO2006131484A1 (en) 2005-06-10 2006-05-31 Indole derivatives having antitumor activity

Publications (1)

Publication Number Publication Date
AU2006256771A1 true AU2006256771A1 (en) 2006-12-14

Family

ID=35062959

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006256771A Abandoned AU2006256771A1 (en) 2005-06-10 2006-05-31 Indole derivatives having antitumor activity

Country Status (13)

Country Link
US (1) US8053460B2 (enExample)
EP (1) EP1891007A1 (enExample)
JP (1) JP2008542428A (enExample)
KR (1) KR20080029967A (enExample)
CN (1) CN101193861A (enExample)
AR (1) AR053891A1 (enExample)
AU (1) AU2006256771A1 (enExample)
BR (1) BRPI0612542A2 (enExample)
CA (1) CA2607337A1 (enExample)
EA (1) EA013542B1 (enExample)
MX (1) MX2007015274A (enExample)
TW (1) TW200716545A (enExample)
WO (1) WO2006131484A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2650810T3 (es) * 2009-01-28 2018-01-22 Karus Therapeutics Limited Isósteros de Scriptaid y su uso en terapia
TWI429628B (zh) * 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
MX364295B (es) * 2012-11-07 2019-04-22 Karus Therapeutics Ltd Inhibidores de histona desacetilasa novedosos y su uso en terapia.
LT2994465T (lt) 2013-05-10 2018-10-10 Karus Therapeutics Limited Nauji histono deacetilazės inhibitoriai
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
RU2633266C2 (ru) * 2015-07-02 2017-10-11 Рауф Ашрафович Ашрафов Способ моделирования карциноидного синдрома
CN105367479A (zh) * 2015-11-16 2016-03-02 青岛大学 一种组蛋白去乙酰酶抑制剂2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基-n-(2-(羟氨基)-2-酮乙基)乙酰胺及其制备方法和应用
CN109928909A (zh) * 2019-04-02 2019-06-25 南华大学 具有抗抑郁活性化合物及其制备方法
CN120136763B (zh) * 2025-03-13 2025-10-10 遵义医科大学 一种c-3苄基化吲哚类化合物、制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887348A1 (en) * 1997-06-25 1998-12-30 Boehringer Mannheim Italia S.p.A. Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them
IT1317925B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Bis-eterocicli ad attivita' antitumorale e chemosensibilizzante.
WO2003032982A1 (en) 2001-10-19 2003-04-24 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
JP4790594B2 (ja) * 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物

Also Published As

Publication number Publication date
TW200716545A (en) 2007-05-01
CN101193861A (zh) 2008-06-04
EA200702672A1 (ru) 2008-04-28
EA013542B1 (ru) 2010-06-30
AR053891A1 (es) 2007-05-23
EP1891007A1 (en) 2008-02-27
US8053460B2 (en) 2011-11-08
BRPI0612542A2 (pt) 2010-11-23
WO2006131484A1 (en) 2006-12-14
CA2607337A1 (en) 2006-12-14
JP2008542428A (ja) 2008-11-27
KR20080029967A (ko) 2008-04-03
MX2007015274A (es) 2008-02-22
US20080207729A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
ES2385831T3 (es) Compuestos para el tratamiento de enfermedades celulares proliferativas
US20090306201A1 (en) Selective inhibitors for transferases
EA001280B1 (ru) Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды
US8053460B2 (en) Indole derivatives having antitumor activity
WO2012127466A1 (en) 5-aminolevulinic acid derivatives, methods for their preparation and uses thereof
JP2005504771A (ja) 抗腫瘍・抗癌剤としてのピペラジノン化合物と処置方法
CN112679492B (zh) 小檗碱衍生物、其制备方法和用途
EP3400210B1 (fr) Composés"multi-cibles"à activité inhibitrice des histone-désacétylases et de la polymérisation de la tubuline pour son utilisation dans le traitement du cancer
AU2002312656B2 (en) Peptoid compounds
Duendar et al. Synthesis of some new 1-acylthiosemicarbazides and 1, 2, 4-triazol-5-thiones, and their analgesic and anti-inflammatory activities
ES2401563T3 (es) Derivados de metilendioxibenzo [I]fenantridina usados para tratar el cáncer
CN105616408A (zh) 吡啶并[3,4-b]吲哚衍生物作为IDO抑制剂的用途
CN102241665B (zh) 4-(4,5-二甲氧羰基-1,3-二硫戊环-2-基)苯甲酰-l-氨基酸苄酯及其合成方法和应用
US6589975B2 (en) Synthetic compounds for treatment of inflammation
WO2023039602A1 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
DK2699580T3 (en) DIAZONAMI DISEASES
US7816386B2 (en) Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumor agents
ES3049841A2 (es) Derivados de histona desacetilasa para el tratamiento del cáncer
JP2019522674A (ja) 抗腫瘍活性を有するベンゾ−ｎ−ヒドロキシアミド化合物
KR20250177242A (ko) 신규한 혈액암 타겟 폴리콤 억제 복합체 2 저해제 및 그 저해제를 포함하는 혈액암 치료용 조성물
JP2025513758A (ja) ２‐［（２‐オキソ‐４‐フェニル‐２ｈ‐クロメン‐７‐イル）オキシ］プロパンアミド誘導体
CN115433176A (zh) 含硫脲结构的almazole D生物碱衍生物及其制备方法和用途
Bakr et al. Synthesis and biological activity of certain new indole derivatives via the utility of 2-acetylindole
HK40045137B (zh) Smad3抑制剂

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application